NASDAQ:LUMO Lumos Pharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.33 +0.08 (+1.10%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$7.25▼$7.6750-Day Range$6.68▼$9.0152-Week Range$6.15▼$11.52Volume6,049 shsAverage Volume8,991 shsMarket Capitalization$61.35 millionP/E RatioN/ADividend YieldN/APrice Target$29.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LUMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LUMO Stock Forecast (MarketRank)Overall MarketRank™2.28 out of 5 starsMedical Sector294th out of 1,411 stocksPharmaceutical Preparations Industry120th out of 672 stocksAnalyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingLumos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.33, Lumos Pharma has a forecasted upside of 300.2% from its current price of $7.33.Amount of Analyst CoverageLumos Pharma has received no research coverage in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesLumos Pharma has received 21 “outperform” votes. (Add your “outperform” vote.)Underperform VotesLumos Pharma has received 7 “underperform” votes. (Add your “underperform” vote.)Community SentimentLumos Pharma has received 75.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Lumos Pharma and other stocks. Vote “Outperform” if you believe LUMO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LUMO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldLumos Pharma does not currently pay a dividend.Dividend GrowthLumos Pharma does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lumos Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,708.00 in company stock.Percentage Held by Insiders15.90% of the stock of Lumos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.35% of the stock of Lumos Pharma is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lumos Pharma are expected to grow in the coming year, from ($3.95) to ($3.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lumos Pharma is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lumos Pharma is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLumos Pharma has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lumos Pharma (NASDAQ:LUMO)Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.Read More LUMO Stock News HeadlinesJune 18, 2022 | americanbankingnews.comLumos Pharma, Inc. (NASDAQ:LUMO) Sees Significant Decline in Short InterestJune 17, 2022 | proactiveinvestors.comLumos Pharma advancing small molecule LUM-201 in Phase 2 studies to treat growth hormone deficiencyJune 9, 2022 | americanbankingnews.comLumos Pharma, Inc. (NASDAQ:LUMO) to Post FY2023 Earnings of ($4.25) Per Share, Cantor Fitzgerald ForecastsMay 10, 2022 | seekingalpha.comLumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 10, 2022 | ca.investing.comLumos Pharma, Inc. Misses Q1 EPS by 3cMay 10, 2022 | finance.yahoo.comLumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development UpdatesMay 9, 2022 | seekingalpha.comLumos Pharma Q1 2022 Earnings PreviewMay 6, 2022 | finance.yahoo.comHere's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn SituationMay 5, 2022 | finance.yahoo.comLumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated TrialApril 26, 2022 | finance.yahoo.comLumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022April 11, 2022 | finance.yahoo.comLumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHDMarch 23, 2022 | finance.yahoo.comLumos Pharma to Participate in the Cantor Rare Disease SymposiumMarch 10, 2022 | benzinga.comRecap: Lumos Pharma Q4 EarningsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LUMO CUSIPN/A CIK1126234 Webwww.lumos-pharma.com Phone(512) 215-2630Fax515-296-3520Employees29Year FoundedN/ACompany Calendar Last Earnings8/05/2021Today6/26/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$29.33 High Stock Price Forecast$35.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+300.2%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30.43 million Net MarginsN/A Pretax Margin-8,843.11% Return on Equity-32.26% Return on Assets-28.50% Debt Debt-to-Equity RatioN/A Current Ratio17.67 Quick Ratio17.67 Sales & Book Value Annual Sales$230 thousand Price / Sales266.75 Cash FlowN/A Price / Cash FlowN/A Book Value$10.65 per share Price / Book0.69Miscellaneous Outstanding Shares8,370,000Free Float7,038,000Market Cap$61.35 million OptionableNot Optionable Beta1.35 Lumos Pharma Frequently Asked Questions Should I buy or sell Lumos Pharma stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Lumos Pharma stock. View analyst ratings for Lumos Pharma or view top-rated stocks. What is Lumos Pharma's stock price forecast for 2022? 3 brokerages have issued 12 month price objectives for Lumos Pharma's shares. Their LUMO stock forecasts range from $25.00 to $35.00. On average, they expect Lumos Pharma's share price to reach $29.33 in the next year. This suggests a possible upside of 300.2% from the stock's current price. View analysts' price targets for Lumos Pharma or view top-rated stocks among Wall Street analysts. How has Lumos Pharma's stock performed in 2022? Lumos Pharma's stock was trading at $6.93 on January 1st, 2022. Since then, LUMO shares have increased by 5.8% and is now trading at $7.33. View the best growth stocks for 2022 here. Are investors shorting Lumos Pharma? Lumos Pharma saw a decline in short interest during the month of May. As of May 31st, there was short interest totaling 16,900 shares, a decline of 15.1% from the May 15th total of 19,900 shares. Based on an average trading volume of 13,000 shares, the short-interest ratio is currently 1.3 days. Approximately 0.4% of the shares of the company are sold short. View Lumos Pharma's Short Interest. When is Lumos Pharma's next earnings date? Lumos Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Lumos Pharma. How were Lumos Pharma's earnings last quarter? Lumos Pharma, Inc. (NASDAQ:LUMO) released its earnings results on Thursday, August, 5th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by $0.03. The company had revenue of $0.01 million for the quarter. View Lumos Pharma's earnings history. Who are Lumos Pharma's key executives? Lumos Pharma's management team includes the following people: Mr. Richard J. Hawkins, CEO & Chairman (Age 73, Pay $950.32k)Dr. John C. McKew Ph.D., Chief Scientific Officer & Pres (Age 58, Pay $804.98k)Ms. Lori D. Lawley CPA, CFO & Principal Accounting Officer (Age 38, Pay $519.11k)Lisa Miller, Sr. Director of Investor RelationsMr. Bradley J. Powers J.D., Chief Compliance Officer & Gen. Counsel (Age 43)Mr. Carl W. Langren, Consultant (Age 67)Mr. Aaron Schuchart B.B.A., CPA, M.B.A., Chief Bus. Officer (Age 57)Dr. David B. Karpf B.A., M.D., Chief Medical Officer (Age 67)Mr. Eddie L. Varnado M.B.A., VP of Fin. & Corp. Controller Who are some of Lumos Pharma's key competitors? Some companies that are related to Lumos Pharma include Clovis Oncology (CLVS), CymaBay Therapeutics (CBAY), XOMA (XOMA), VBI Vaccines (VBIV), G1 Therapeutics (GTHX), Verastem (VSTM), Theseus Pharmaceuticals (THRX), Theratechnologies (THTX), AVEO Pharmaceuticals (AVEO), Viking Therapeutics (VKTX), Vaccitech (VACC), Rhythm Pharmaceuticals (RYTM), Nature's Sunshine Products (NATR), Pardes Biosciences (PRDS) and Aldeyra Therapeutics (ALDX). View all of LUMO's competitors. What other stocks do shareholders of Lumos Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), (NCLH), Northern Oil and Gas (NOG), Agilent Technologies (A), Air Lease (AL), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and CorMedix (CRMD). What is Lumos Pharma's stock symbol? Lumos Pharma trades on the NASDAQ under the ticker symbol "LUMO." Who are Lumos Pharma's major shareholders? Lumos Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.25%), BlackRock Inc. (0.71%), Private Advisor Group LLC (0.34%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Lumos Pharma stock include James E Flynn, John C Mckew, Kevin M Lalande and Kevin M Lalande. View institutional ownership trends for Lumos Pharma. Which major investors are selling Lumos Pharma stock? LUMO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and BlackRock Inc.. Company insiders that have sold Lumos Pharma company stock in the last two years include James E Flynn, and John C Mckew. View insider buying and selling activity for Lumos Pharma or view top insider-selling stocks. Which major investors are buying Lumos Pharma stock? LUMO stock was purchased by a variety of institutional investors in the last quarter, including Private Advisor Group LLC. View insider buying and selling activity for Lumos Pharma or or view top insider-buying stocks. How do I buy shares of Lumos Pharma? Shares of LUMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lumos Pharma's stock price today? One share of LUMO stock can currently be purchased for approximately $7.33. How much money does Lumos Pharma make? Lumos Pharma (NASDAQ:LUMO) has a market capitalization of $61.35 million and generates $230 thousand in revenue each year. The company earns $-30.43 million in net income (profit) each year or ($3.54) on an earnings per share basis. How many employees does Lumos Pharma have? Lumos Pharma employs 29 workers across the globe. How can I contact Lumos Pharma? Lumos Pharma's mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The official website for Lumos Pharma is www.lumos-pharma.com. The company can be reached via phone at (512) 215-2630, via email at [email protected], or via fax at 515-296-3520. This page (NASDAQ:LUMO) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
